Editor’s Special Episode: ASCO 2025 Highlights in AML with Dr. Amir Fathi

In this Editor’s Special of The HemOnc Pulse, Blood Cancers Today Managing Editor, Nichole Tucker speaks with Amir Fathi, MD, of Massachusetts General Hospital, about key updates in AML from ASCO 2025. The discussion centers on a phase 2 study of an all-oral regimen—decitabine and cedazuridine plus venetoclax—for patients with newly diagnosed AML who are unfit for intensive induction.

Dr. Fathi discusses the potential for these more convenient therapies to shift treatment into the outpatient setting while maintaining effectiveness. He also shares insights on promising triplet regimens incorporating targeted therapies and highlights the need for new strategies for patients with resistant disease subtypes, such as TP53-mutated or venetoclax-refractory AML.

Looking ahead, Dr. Fathi previews anticipated data from menin inhibitor trials and the phase 3 Quantum Wild study. This episode is a must-listen for clinicians and researchers interested in the future of AML care.